Fasudil protects cultured N1E-115 cells against lysophosphatidic acid-induced neurite retraction through inhibition of Rho-kinase

Brain Research Bulletin

Volumn 84, Issue 2, 2011, Pages 174-177

  Satoh, Shin Ichi ^a   Kawasaki, Koh ^a   Hitomi, Asako ^a   Ikegaki, Ichiro ^a   Asano, Toshio ^a  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Fasudil; Lysophosphatidic acid; N1E 115 cell; Neurite retraction; Rho kinase

Indexed keywords

FASUDIL; HYDROXYFASUDIL; LYSOPHOSPHATIDIC ACID; MYOSIN; MYOSIN SUBFRAGMENT; PHOSPHATASE; RHO KINASE;

ARTICLE; BRAIN DAMAGE; CELL CULTURE; CELL POPULATION; CELL PROTECTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; NERVE FIBER GROWTH; NEURITE; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELL LINE; HUMANS; LYSOPHOSPHOLIPIDS; MICE; NEURITES; NEURONS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 79451473007     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.11.013     Document Type: Article

References (25)

1. Amano M., Chihara K., Nakamura N., Fukata Y., Yano T., Shibata M., Ikebe M., Kaibuchi K. Myosin II activation promotes neurite retraction during the action of the Rho and Rho-kinase. Genes Cells 1998, 3:177-188.
2. M. Berry, Z. Ahmed, M.R. Douglas, A. Logan, Epidermal growth factor receptor antagonists and CNS axon regeneration: mechanisms and controversies, Brain Res. Bull., in press.
3. Feske S.K., Sorond F.A., Henderson G.V., Seto M., Hitomi A., Kawasaki K., Sasaki Y., Asano T., Liao J.K. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 2009, 1257:89-93.
4. Fukushima N. LPA in neural cell development. J. Cell Biochem. 2004, 92:993-1003.
5. Hirose M., Ishizaki T., Watanabe N., Uehata M., Kranenburg O., Moolenaar W.H., Matsumura F., Maekawa M., Bito H., Narumiya S. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J. Cell Biol. 1998, 141:1625-1636.
6. 2α-induced contraction of rabbit aortae. J. Physiol. 2003, 546:823-836.
7. Kawasaki K., Yano K., Sasaki K., Tawara S., Ikegaki I., Satoh S., Ohtsuka Y., Yoshino Y., Kuriyama H., Asano T., Seto M. Correspondence between neurological deficit, cerebral infarct size, and Rho-kinase activity in a rat cerebral thrombosis model. J. Mol. Neurosci. 2009, 39:59-68.
8. Kim S.Y., Shin D.H., Kim S.J., Koo B.S., Bae C.D., Park J., Jeon S. Chloride channel conductance is required for NGF-induced neurite outgrowth in PC12 cells. Neurochem. Int. 2010, 56:663-669.
9. Maiese K., Wagner J., Boccone L. Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade. Neurosci. Lett. 1994, 166:43-47.
10. Moolenaar W.H. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol. 1994, 4:213-219.
11. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., Asano T. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn. J. Pharmacol. 1999, 80:41-48.
12. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., Asano T. Pharmacological profile of hydroxyl fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001, 69:1441-1453.
13. Satoh S., Toshima Y., Ikegaki I., Iwasaki M., Asano T. Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils. Brain Res. 2007, 1128:175-180.
14. Satoh S., Toshima Y., Hitomi A., Ikegaki I., Seto M., Asano T. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res. 2008, 1193:102-108.
15. Satoh S., Hitomi A., Ikegaki I., Kawasaki K., Nakazono O., Iwasaki M., Mohri M., Asano T. Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res. Bull. 2010, 81:191-195.
16. Shibuya M., Suzuki Y., Sugita K., Saito I., Sasaki T., Takakura K., Nagata I., Kikuchi H., Takemae T., Hidaka H., Nakashima M. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J. Neurosurg. 1992, 76:571-577.
17. Shibuya M., Hirai S., Seto M., Satoh S., Ohtomo E. Effects of fasudil in acute ischemic stroke. Results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005, 238:31-39.
18. Shimokawa H., Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1767-1775.
19. 2-derived arachidonic acid and its metabolites. Brain Res. 1996, 721:39-48.
20. Suzuki Y., Shibuya M., Satoh S., Sugimoto Y., Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 2007, 68:126-132.
21. Suzuki Y., Shibuya M., Satoh S., Sugiyama H., Seto M., Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage. Sub-analysis of the post-marketing surveillance study. Neurol. Med. Chir. (Tokyo) 2008, 48:241-248.
22. Cip1/WAF1 enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 2004, 127:155-164.
23. Toshima Y., Satoh S., Ikegaki I., Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31:2245-2250.
24. Wylie S.R., Chantler P.D. Myosin IIA drives neurite retraction. Mol. Biol. Cell 2003, 14:4654-4666.
25. Yagita Y., Kitagawa K., Sasaki T., Terasaki Y., Todo K., Matsuoka E., Kaibuchi K., Hori M. Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J. Neurosci. Res. 2007, 85:2460-2469.